ARTICLE | Product Development

Setting Oxygen Free

December 7, 2009 8:00 AM UTC

Lack of sufficient oxygen in tissues is implicated as a causal factor in a variety of diseases ranging from cardiovascular disease and cancer to macular degeneration. NormOxys Inc. believes its oxyren small molecules, which enhance hemoglobin's ability to release oxygen, can treat and modify these diseases by normalizing oxygen pressure in tissues without the risk of hyperoxygenation.

The company's lead compound, OXY111A, is slated to enter Phase I trials next quarter...